18 / 18
Page 60
Notes:
conferenceseries
.com
Volume 6
General Medicine: Open Access
ISSN: 2327-5146
Emergency Nursing 2018
Cancer Nursing 2018
July 16-17, 2018
July 16-17, 2018 | London, UK
26
th
CancerNursing&NursePractitionersConference
&
5
th
Annual Congress on
EmergencyNursing&CriticalCare
JOINT EVENT
The effect of the anti-cancer preparation NSC-631570 on prostate cancer
Wassil Nowicky
Nowicky Pharma, Ukrainian Anti-Cancer Institute, Austria
U
nusual for an anticancer agent NSC 631570 possesses some distinct immune properties. In several immune target-
effector systems NSC 631570 significantly amplified the malignotoxic activity of macrophages, lymphocytes and natural
killer (NK) cells, and stimulates dendritic cells maturation in vitro. While the parameters like B-lymphocytes count, immune
globulin concentrations, complement and acute phase proteins did not changed significantly, it can be postulated NSC 631570
modulates the cellular part of the immune system whereas the humoral part remains unaffected. Besides, the NSC631570 has
a selective effect – thus, it kills only cancer cells and the healthy cells remain undamaged. First indications on the selective
effect of NSC 631570 on the cancer cells were provided in an early study when different oxygen consumption by normal liver
cells and Ehrlich’s tumor ascitic cells after the incubation with NSC 631570 was revealed. A radio protective effect was found
in normal human fibroblasts. NSC 631570 caused the accumulation of prostate cancer cells as well as epidermoid carcinoma
cells in the G2/M phase, however, not of normal cells. The efficacy of NSC-631570 in prostate cancer has been confirmed in
a controlled clinical study. In the study patients, all standard treatment modalities had been exhausted. The cancer relapsed
and/or progressed and no therapy protocol was available. The patients were treated with NSC-631570 and partially with local
hyperthermia. Following results were achieved: full remission in 54 patients (73%), partial remission in 16 patients (22%).
Only in 4 patients (5%) the therapy did not affect the course of the disease.
Biography
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute, Vienna, Austria. He has finished his study at the Radio
technical Faculty of the Technical University of Lviv (Ukraine) in 1955 with graduation in Diplom-Ingeniueur in 1960 with title nostrificated in Austria in 1975. He
became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on
basis of celandine alkaloids NSC-631570. He used the factor that cancer cells are more negative charged than normal cells and invented the celandine alkaloid
with a positive charge thanks to which it accumulates in cancer cells very fast. He is an author of over 300 scientific articles dedicated to cancer research. He is a
member of the New York Academy of Sciences, member of the European Union for Applied Immunology and of the American Association for scientific progress,
Honorary Doctor of the Janka Kupala University in Hrodno, Doctor Honoris Causa of the Open International University on complex medicine in Colombo, Honorary
Member of the Austrian Albert Schweitzer Society. He has received the award for merits of National guild of pharmacists of America; the award of Austrian Society
of sanitary, hygiene and public health services and others.
dr.nowicky@yahoo.deWassil Nowicky, Gen Med (Los Angeles) 2018, Volume 6
DOI: 10.4172/2327-5146-C2-005